Ceapro Inc. Reports 2020 Second Quarter and Six-Month Financial Results and Operational Highlights

Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history –

– R&D activities focused on the development of innovative delivery systems –

– Net profit of $1,077,000 for Q2 2020 vs. net loss of $559,000 for Q2 2019 –

– Cash generated from operations of $2,727,000 in 2020 vs $853,000 in 2019 –

– Maintained production operations during COVID-19 pandemic, providing our customers with essential products while ensuring the health and safety of our employees –

EDMONTON, Alberta, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and the first six months ended June 30, 2020.

“We are extremely proud of our employees who worked tirelessly since the beginning of the year to deliver these excellent results despite the COVID-19 pandemic. Progress was made on all fronts from production operations with the largest volumes produced in Ceapro’s history to Research Engineering where the PGX group has successfully developed and optimized new products like yeast beta glucan as a potential inhalable therapeutic for COVID-19. As we continue to move forward and navigate operations during these unprecedented times, our focus remains on the health and safety of our associates, followed by business continuity,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.

Corporate and Operational Highlights

Pipeline Development:

  • Announced expansion of collaborative research program with McMaster University to develop inhalable therapeutic for COVID-19;
  • Announced publication of positive results for a PGX-processed drug delivery system for accelerated burn wound healing;
  • Pursued the development of new PGX-dried chemical complexes for potential applications under various forms like pills, capsules, fast dissolving strips and face masks; and
  • Continued the monitoring of stability studies for liquid beta glucan and avenanthramides produced at the new manufacturing site as well as for the pharmaceutical grade dry powder formulation of avenanthramides.


  • Made significant technical upgrades of PGX demo plant;
  • Completed technical assessment of available pieces of equipment world-wide for final decision on the type and location of future commercial scale PGX unit; and
  • Executed on research collaboration projects with University of Alberta and McMaster University for the impregnation of various bio actives using PGX-processed dry beta glucan and alginate as potential delivery systems for multiple applications in healthcare. 

Production Operations:

  • Delivered the largest quantity of final product in Ceapro’s history; and
  • Initiated decommissioning of Leduc manufacturing site.


  • Advanced conversations with interested potential partners to utilize Ceapro’s innovative technologies; and
  • Pursued out-licensing discussions for PGX-processed new chemical complexes.

Subsequent to Quarter:

  • Announced publication of positive results from study evaluating avenanthramides in exercise-induced inflammation; and
  • Announced successful development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 and other fibrotic end-point diseases of the lung.

Financial Highlights for the Second Quarter and the Six Month Period Ended June 30, 2020

  • Total sales of $4,666,000 for the second quarter of 2020 and $8,939,000 for the first six months of 2020 compared to $3,054,000 and $6,251,000 for the comparative periods in 2019. The 43% increase in sales for the first six months is mainly due to a significant increase in sales of avenanthramides as well as an increase in sales of beta glucan to China, compared to the same period in 2019.
  • Net profit of $1,077,000 for the second quarter of 2020 and $2,203,000 for the first six months of 2020 compared to a net loss of $559,000 and $1,195,000 for the comparative periods in 2019.
  • Excluding non-cash items, mainly amortization, adjusted net profit for the first six months in 2020 is $ 3,323,000 versus adjusted net loss of $24,600 for the first six months of 2019.
  • Cash flows generated from operations of $2,727,000 in 2020 vs $853,000 in 2019.
  • Positive working capital balance of $7,732,000 as of June 30, 2020.
  • Subsequent to quarter, made final payment clearing loan with Alberta Financial Service Corporation.

"Over the course of the second quarter, our operations executed and adapted well, delivering significantly improved  results on both a sequential and year-over-year basis. This strong performance resulted in a record quarter for the Company, highlighting the resiliency of our business model focused on providing customers with essential, sustainable high-quality products. The ability of our business to successfully navigate through the challenging second quarter business environment is a testament to the commitment and hard work of our dedicated employees, and a measurable indication of the operational improvements and cost reduction initiatives being generated by our strategic investments of the past few years,” continued Mr. Gagnon.

“Looking ahead, while taking into account the ongoing potential economic impact related to COVID-19 and evolving consumption trends, we believe Ceapro is well-positioned to once again deliver a solid double-digit growth in sales over 2019. With a strong balance sheet, a group of dedicated people, and a solid base business coupled with the innovative technologies and products that we have developed to enable us to expand, Ceapro is poised to emerge as a successful Life Science company,” concluded Mr. Gagnon.

Consolidated Balance Sheets    
  June 30, December 31,
  2020 2019
  $ $
Current Assets    
Cash and cash equivalents 4,267,320 1,857,195
Trade receivables 3,058,551 3,659,541
Other receivables 90,411 46,812
Inventories (note 3) 1,261,494 669,005
Prepaid expenses and deposits 262,199 178,908
  8,939,975 6,411,461
Non-Current Assets    
Investment tax credits receivable 607,700 607,700
Deposits 85,755 85,755
Licences (note 4) 19,995 21,477
Property and equipment (note 5) 18,883,313 19,764,122
Deferred tax assets 378,643 378,643
  19,975,406 20,857,697
TOTAL ASSETS 28,915,381 27,269,158
Current Liabilities    
Accounts payable and accrued liabilities 843,004 1,291,204
Current portion of long-term debt (note 6) 15,466 111,865
Current portion of lease liabilities (note 7) 272,145 265,123
Current portion of CAAP loan (note 9) 77,858 72,942
  1,208,473 1,741,134
Non-Current Liabilities    
Long-term lease liabilities (note 7) 2,637,776 2,775,627
CAAP loan (note 9) 67,074 61,580
Deferred tax liabilities 378,643 378,643
  3,083,493 3,215,850
TOTAL LIABILITIES 4,291,966 4,956,984
Share capital (note 8 (b)) 16,503,089 16,401,677
Contributed surplus (note 8 (e)) 4,656,825 4,650,090
Retained earnings 3,463,501 1,260,407
  24,623,415 22,312,174
TOTAL LIABILITIES AND EQUITY 28,915,381 27,269,158

CEAPRO INC.        
Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
  Quarters Ended June 30,   Six Months Ended June 30,  
  2020   2019   2020 2019  
   $    $    $  $  
Revenue (note 15)   4,665,971     3,053,727     8,939,345   6,250,657  
Cost of goods sold   2,079,270     1,592,293     3,980,493   3,432,591  
Gross margin   2,586,701     1,461,434     4,958,852   2,818,066  
Research and product development   399,797     811,894     902,339   1,612,398  
General and administration   838,263     878,620     1,703,297   1,611,639  
Sales and marketing   29,207     95,102     77,435   202,780  
Finance costs (note 12)   44,583     52,813     146,192   161,187  
Income (loss) from operations   1,274,851     (376,995 )   2,129,589   (769,938 )
Other income (expenses) (note 11)   (197,812 )   (181,596 )   73,505   (425,281 )
Income (loss) before tax   1,077,039     (558,591 )   2,203,094   (1,195,219 )
Income taxes   -      -      -    -   
Total comprehensive income (loss) for the period   1,077,039     (558,591 )   2,203,094   (1,195,219 )
Net income (loss) per common share (note 18):        
Basic   0.01     (0.01 )   0.03   (0.02 )
Diluted   0.01     (0.01 )   0.03   (0.02 )
Weighted average number of common shares outstanding (note 18):        
Basic   77,608,341     77,053,836     77,573,327   77,050,330  
Diluted   77,980,876     77,053,836     77,930,529   77,050,330  

Consolidated Statements of Cash Flows    
  2020   2019  
Six Months Ended June 30, $   $  
Net income (loss) for the period 2,203,094   (1,195,219 )
Adjustments for items not involving cash    
Finance costs 79,674   88,546  
Transaction costs 1,108   3,080  
Depreciation and amortization 920,521   912,751  
Foreign exchange gain on long-term debt -   (307 )
Accretion 10,410   14,561  
Share-based payments 108,147   152,017  
Net income (loss) for the period adjusted for non-cash items 3,322,954   (24,571 )
Trade receivables 600,990   795,136  
Other receivables (43,599 ) 24,248  
Inventories (592,489 ) (192,553 )
Prepaid expenses and deposits (33,088 ) 219,940  
Accounts payable and accrued liabilities relating to operating activities (448,200 ) 119,050  
Total changes in non-cash working capital items (516,386 ) 965,821  
Net income (loss) for the period adjusted for non-cash and working capital items 2,806,568   941,250  
Interest paid (79,674 ) (88,546 )
Purchase of property and equipment (38,230 ) (27,611 )
Deposits relating to investment in equipment (50,203 ) (53,239 )
Accounts payable and accrued liabilities relating to investing activities -   (1,458 )
Stock options exercised -   13,783  
Repayment of long-term debt (97,507 ) (241,044 )
Repayment of lease liabilities (130,829 ) (138,541 )
Increase in cash and cash equivalents 2,410,125   404,594  
Cash and cash equivalents at beginning of the period 1,857,195   1,844,134  
Cash and cash equivalents at end of the period 4,267,320   2,248,728  

The complete financial statements are available for review on SEDAR at https://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00010110 and on the Company’s website at www.ceapro.com.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Ceapro Logo.jpg

Source: Ceapro Inc.